Login
Cardiovascular Systems NASDAQ: CSII
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
| Name | Cardiovascular Systems |
| Ticker | CSII |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Medical Devices |
|
Price
52W Low/High |
37.62
27.86 / 47.19 |
| Momentum | Weak Down |
| Market cap | 1.5 B |
| 1Y Total Return |
10.29%
Weak |
| 1Y Volatility |
40.89%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
Details
| Ticker | CSII |
| Name | Cardiovascular Systems |
| ISIN | US1416191062 |
| CUSIP | 141619106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 5/18/21
| Close Price | 37.62 |
| 52W Low/High | 27.86 / 47.19 |
| Market cap | 1.5 B |
| 1Y Total Return |
10.29%
Weak |
| 1Y Volatility |
40.89%
Average Risk |
| Beta | 1.52 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -10.1% |
| Cash from Op. / Cur. Liabilities | -0.27 |
| Diluted Earnings / Share | -0.64 |
| ROE | - |
| ROIC | -13.5% |
| Price / Revenue | 6.3 |
| Price / Book | 5.4 |
| Price / CF | -106.4 |
| Current Ratio | 5.7 |
| Cur.Liabilities / Tot.Liabilities | 0.7 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
231
|
262
|
239
|
211
|
200
|
178
|
|
| Gross Profit |
180
|
210
|
194
|
172
|
161
|
142
|
|
| R&D |
44
|
41
|
30
|
26
|
23
|
28
|
|
| EBITDA |
-17
|
-5
|
8
|
5
|
-3
|
-56
|
|
| Operating Income |
-22
|
-11
|
2
|
-1
|
-8
|
-60
|
|
| Net Income exc. Extra |
-
|
-
|
2
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
39
|
34
|
34
|
34
|
33
|
33
|
|
| EPS exc. Extra |
-0.64
|
-0.31
|
0.05
|
-0.04
|
-0.23
|
-1.84
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
347
|
220
|
211
|
195
|
187
|
145
|
|
| Cash, Eq & Invt ShortTerm |
211
|
107
|
116
|
110
|
104
|
64
|
|
| Total Current Assets |
285
|
164
|
172
|
161
|
152
|
107
|
|
| Total Non-Current Assets |
62
|
56
|
39
|
34
|
35
|
38
|
|
| Intangibles |
16
|
20
|
5
|
5
|
5
|
5
|
|
| Total Liabilities |
76
|
77
|
70
|
68
|
73
|
43
|
|
| Total Current Liabilities |
50
|
50
|
40
|
36
|
39
|
35
|
|
| Long Term Debt |
26
|
27
|
29
|
32
|
35
|
8
|
|
| Shareholder equity |
270
|
143
|
142
|
126
|
113
|
102
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-14
|
4
|
13
|
5
|
13
|
-27
|
|
| Depreciation |
4
|
4
|
4
|
4
|
4
|
4
|
|
| Cash from Investing |
-115
|
-47
|
-9
|
-3
|
-1
|
-8
|
|
| Capex |
4
|
3
|
3
|
2
|
1
|
7
|
|
| Cash from Financing |
134
|
-3
|
2
|
4
|
29
|
4
|
|
| Stock Issued |
139
|
4
|
4
|
4
|
8
|
4
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
21
|
0
|
|
| Free Cash Flow |
-31
|
-2
|
-1
|
-6
|
-9
|
-60
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
0.8%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
761.1%
|
-
|
-
|
-
|
|
| Current Ratio |
5.7
|
3.3
|
4.3
|
4.5
|
3.9
|
3.1
|
|
| Financial Leverage D/E |
0.08
|
0.15
|
0.15
|
0.17
|
0.18
|
0.00
|
|
| Return on Capital Avg |
-13.5%
|
-10.1%
|
8.6%
|
1.3%
|
-15.7%
|
-121.1%
|
|
| Return on Shareholder Equity |
-
|
-
|
1.5%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available